9ELV
 
 | | Crystal Structure of SARS-CoV-2 Mpro mutant E166V with Pfizer Intravenous Inhibitor PF-00835231 | | Descriptor: | 3C-like proteinase nsp5, GLYCEROL, N-[(2S)-1-({(2S,3S)-3,4-dihydroxy-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl}amino)-4-methyl-1-oxopentan-2-yl]-4-methoxy-1H-indole-2-carboxamide | | Authors: | Zvornicanin, S.N, Shaqra, A.M, Schiffer, C.A. | | Deposit date: | 2024-12-05 | | Release date: | 2025-03-19 | | Last modified: | 2025-05-21 | | Method: | X-RAY DIFFRACTION (1.62 Å) | | Cite: | Molecular mechanisms of drug resistance and compensation in SARS-CoV-2 main protease: the interplay between E166 and L50.
Mbio, 16, 2025
|
|
9EL4
 | | Crystal Structure of SARS-CoV-2 Mpro mutant E166A with Pfizer Intravenous Inhibitor PF-00835231 | | Descriptor: | 3C-like proteinase nsp5, GLYCEROL, N-[(2S)-1-({(2S,3S)-3,4-dihydroxy-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl}amino)-4-methyl-1-oxopentan-2-yl]-4-methoxy-1H-indole-2-carboxamide | | Authors: | Zvornicanin, S.N, Shaqra, A.M, Schiffer, C.A. | | Deposit date: | 2024-12-03 | | Release date: | 2025-03-19 | | Last modified: | 2025-05-21 | | Method: | X-RAY DIFFRACTION (1.88 Å) | | Cite: | Molecular mechanisms of drug resistance and compensation in SARS-CoV-2 main protease: the interplay between E166 and L50.
Mbio, 16, 2025
|
|
9MEI
 | | Crystal Structure of SARS-CoV-2 Mpro mutant L50F E166V with Pfizer Intravenous Inhibitor PF-00835231 | | Descriptor: | 3C-like proteinase nsp5, CHLORIDE ION, DIMETHYL SULFOXIDE, ... | | Authors: | Zvornicanin, S.N, Shaqra, A.M, Schiffer, C.A. | | Deposit date: | 2024-12-06 | | Release date: | 2025-03-19 | | Last modified: | 2025-05-21 | | Method: | X-RAY DIFFRACTION (1.84 Å) | | Cite: | Molecular mechanisms of drug resistance and compensation in SARS-CoV-2 main protease: the interplay between E166 and L50.
Mbio, 16, 2025
|
|
